Anti-viral compounds
View Patent ↗Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
1. A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula II:
wherein:
R 6 is selected from the group consisting of hydrogen and cyano;
R 8 is selected from the group consisting of hydrogen and arylalkyl;
R 25 is selected from the group consisting of hydrogen and alkyl;
R 37 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl;
R 42 is selected from the group consisting of arylsulfanyl, heteroarylsulfanyl, and aryloxy; wherein R 42 is optionally substituted with one or more substituents independently selected from R 46 ;
R 46 is one or more substituents selected from the group consisting of hydrogen, hydroxy, amino, halogen, dialkylamino, and alkoxycarbonylamino;
R 70 is selected from the group consisting of aryl, and heterocyclo; wherein R 70 is optionally substituted with R 75 ;
R 75 is one or more substituents independently selected from the group consisting of hydrogen, halogen, alkoxy, cyano, alkyl, haloalkyl, and aryl.
2. A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula III:
wherein R 80 is selected from the group consisting of hydrogen, alkylcarbonyl, and haloaryl.
3. A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula VII:
wherein:
A is selected from the group consisting of O and S;
R 21 is selected from the group consisting of hydrogen and hydroxy;
or R 21 taken together with R 39 form a 5-12 membered heterocycle containing at least two heteroatoms selected from the group consisting of O, N, and S; or
R 39 is selected from the group consisting of hydrogen, alkyl, arylalkenyl, dialkylamino, heteroaryl, haloheteroaryl, haloarylaminosulfonyl, arylsulfonyloxy, alkylcarbonyloxy, cycloalkylaminocarbonyl, arylalkoxycarbonylamino, alkoxycarbonyl, and NH—R 99 ;
R 99 is selected from the group consisting of hydrogen, arylalkyl, cycloalkylalkyl, aryl, heteroaryl, haloarylalkylamino, arylalkylamino, and alkylheteroaryl;
R 67 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and alkylcycloalkyl;
R 96 is selected from the group consisting of hydrogen, hydroxy, amino, alkoxy, arylsulfonyloxy, alkylcarbonylamino, alkoxy, halogen, alkoxycarbonyloxy, haloalkoxycarbonylamino, and arylalkoxy.